Charles River Laboratories and Chiesi Farmaceutici SpA Announce Extension of Integrated Respiratory Drug Discovery Program
13 March 2017 - 11:00PM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL), a
leading early-stage contract research organization (CRO), today
announced that it has extended its longstanding, strategic,
integrated drug discovery partnership with Chiesi Farmaceutici SpA
in the field of respiratory disease.
“Over the past six years, our integrated respiratory program
with Chiesi has been extremely productive,” said Birgit Girshick,
Corporate Senior Vice President, Global Discovery at Charles River.
“Together, our teams have generated a significant number of patents
and development candidates, showing the true power of collaboration
in driving safe and effective treatments to the clinic.”
Through their continued partnership, Charles River will provide
Chiesi an extensive portfolio of integrated drug discovery
capabilities, including medicinal chemistry, ADME/DMPK studies,
pharmaceutics, in vitro assays, in vivo models, and safety
pharmacology studies to help identify and test Chiesi’s promising
candidates for preclinical development.
“Charles River has a long track record in conducting inhaled
drug discovery and development studies,” said Dr. Mark Parry
Billings, Corporate Drug Development Head, Chiesi Farmaceutici.
“This, coupled with their expertise in end-to-end respiratory drug
design, has made Charles River a strong partner for us in the field
of respiratory research. We look forward to continuing our
relationship with their team.”
Charles River and Chiesi have engaged in an ongoing program
since 2011, with the latest extension paving the way for a durable
continuation. In addition to their longstanding relationship with
Chiesi, Charles River has been active in the respiratory research
space for more than 16 years. In that time, Charles River’s
scientists have been named as co-inventors on nearly 70 respiratory
patents filed by their clients and produced 25 development
candidates.
About Chiesi Farmaceutici
Headquartered in Parma, Italy, Chiesi Farmaceutici is an
international research-focused Healthcare group, with over 80 years
of experience in the pharmaceutical industry. Chiesi researches,
develops and markets innovative drugs in the respiratory
therapeutics, specialist medicine and rare diseases areas. Its
R&D organization is headquartered in Parma (Italy), and
integrated with other 6 key R&D groups in France, USA, UK,
Sweden and Denmark to advance Chiesi's pre-clinical, clinical and
registration programs. Chiesi employs over 4,500 people, 560 of
whom are solely dedicated to R&D activities. For more
information, please visit www.chiesi.com.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170313005124/en/
Charles River Laboratories International, Inc.Investor
Contact:Susan E. Hardy, 781-222-6190Corporate Vice President,
Investor Relationssusan.hardy@crl.comorMedia Contact:Amy
Cianciaruso, 781-222-6168Corporate Vice President, Public
Relationsamy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2024 to May 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From May 2023 to May 2024